EUCTR2009-013884-21-BE进行中（未招募）1 期
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who are eligible for inclusion will be female or male patients, 18 to 65 years of age (inclusive), who have a diagnosis of RRMS (per McDonald criteria, 2005) with dissemination in time and space or a diagnosis of CIS confirmed by MRI. Patients with CIS who only have optic neuritis will be excluded from this study, a maximum Expanded Disability Status Scale (EDSS) score of = 6.0, who have new neurological symptoms or exacerbation of prior neurological symptoms of over 24 hours duration but <7 days duration, verified by neurological examination and who have signed an informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be excluded from participation in the study who have
- •-Primary progressive MS.
- •-Secondary progressive MS without superimposed relapses.
- •-Received systemic corticosteroids within 4 weeks of screening for treatment of MS or other conditions. If non-systemic steroids (topical, inhalation, ocular) are being used for other chronic inflammatory conditions, patients may be included at the discretion of the investigator after discussion with the medical monitor.
- •-Known contraindications or hypersensitivity to parenteral steroids e.g. systemic infection such as mycoses or parasitoses, acute viral infections (herpes zoster, herpes simplex, varicella), hepatitis B surface antigen (HBsAg) positive chronic active hepatitis, immunisations within recent weeks, lymphadenitis after Bacille Calmette-Guérin (BCG) vaccination, history of psychiatric problems including prior steroid psychosis, gastroduodenal or -intestinal ulcer, uncontrolled hypertension, severe osteoporosis and narrow- and wide-angle glaucoma
- •-Previous treatment with azathioprine, mitoxantrone, natalizumab, intravenous immunoglobulin or plasmapheresis in the last 6 months.
- •-Women who are lactating, pregnant (positive pregnancy test at Screening), or planning to become pregnant during the course of the study.
- •-Unwillingness to use reliable and acceptable contraceptive methods (e.g. implants, injectables, combined oral contraceptives, intrauterine devices [IUDs], sexual abstinence or vasectomised partner) throughout the study and till 3 months after last study medication administration except for female patients who are surgically sterile (post hysterectomy or at least 1 year post tubal ligation) or at least 2 years postmenopausal.
- •-Any concurrent illness, disability or clinically significant abnormality that may affect the interpretation of clinical efficacy or safety data or prevent the subject from safely completing the assessments required by the protocol.
- •- History of malignancy within the last 5 years with exception of basal cell skin carcinoma
- •- Chronic diseases of the immune system, malignancies, acute pulmonary disease, cardiac failure, severe depression etc. or unstable medical conditions.
- •-Cardiac pacemaker or any other type of metal implant or with any other contraindication for MRI (including known allergy to gadolinium).
- •-Participation in another clinical study within 60 days of screening.
- •- Recent history or suspicion of current drug abuse (including analgesic abuse) or alcohol abuse within the last 6 months prior to Screening.
- •- Medical, psychiatric, cognitive, or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study.
- •- Known history of diabetes mellitus.
- •- History of any other than MS autoimmune conditions or immunodeficiency syndromes.
研究者
相似试验
进行中（未招募）
不适用
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated SyndromeMedDRA version: 14.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-013884-21-DEEnceladus Pharmaceuticals BV90
进行中（未招募）
不适用
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated SyndromeMedDRA version: 14.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-013884-21-PLEnceladus Pharmaceuticals BV90
进行中（未招募）
1 期
A Randomised, International, Multicenter Study to assess the Efficacy and Safety of Mesalazine EC tablets 500 mg (4.5g/daily) and Salofalk® tablets 500 mg (4.5 g/daily) in the Treatment of Moderate Active Crohn diseaseEUCTR2004-004083-77-SKDisphar International B.V.436
进行中（未招募）
不适用
A Randomised, International, Multicenter Study to assess the Efficacy and Safety of Mesalazine EC tablets 500 mg (4.5g/daily) and Salofalk® tablets 500 mg (4.5 g/daily) in the Treatment of Moderate Active Crohn diseaseModerate active Crohn diseaseEUCTR2004-004083-77-CZDisphar International B.V.436
进行中（未招募）
不适用
This is a study to evaluate a radioactive agent that helps to detect signs ofchanges in the brain, indicating reduced brain function in thinking.Alzheimer's DiseaseEUCTR2012-002595-13-ITAVID RADIOPHARMACEUTICALS, INC.600